MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

Search

Amicus Therapeutics Inc

Fermé

SecteurSoins de santé

5.97 -5.09

Résumé

Variation du prix de l'action

24h

Actuel

Min

5.91

Max

6.29

Chiffres clés

By Trading Economics

Revenu

-36M

-22M

Ventes

-24M

125M

Marge bénéficiaire

-17.314

Employés

499

EBITDA

-27M

-4.8M

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+154.37% upside

Dividendes

By Dow Jones

Prochains Résultats

7 août 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-349M

1.9B

Ouverture précédente

11.06

Clôture précédente

5.97

Sentiment de l'Actualité

By Acuity

11%

89%

13 / 376 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Very Strong Bearish Evidence

Amicus Therapeutics Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

17 juil. 2025, 23:34 UTC

Acquisitions, Fusions, Rachats

FTC Reopens Consent Orders for Proposed Acquisitions from Exxon Mobil, Chevron

17 juil. 2025, 21:14 UTC

Acquisitions, Fusions, Rachats

Basel Medical Group Puts $1 Billion Bitcoin Purchase on Hold

17 juil. 2025, 21:04 UTC

Principaux Mouvements du Marché
Acquisitions, Fusions, Rachats

Norfolk Southern Shares Rise on WSJ Report of Union Pacific Acquisition Interest

17 juil. 2025, 23:43 UTC

Market Talk

Gold Edges Higher on Possible Position Adjustments -- Market Talk

17 juil. 2025, 23:42 UTC

Market Talk

Nikkei May Rise on Signs of U.S. Econ Strength -- Market Talk

17 juil. 2025, 22:47 UTC

Acquisitions, Fusions, Rachats

FTC: Maintaining Restrictions for Former Pioneer CEO Scott Sheffield Would Damage FTC's Credibility

17 juil. 2025, 22:46 UTC

Acquisitions, Fusions, Rachats

Potential Rail Merger Could Prompt Berkshire Hathaway to Bid for CSX -- Barrons.com

17 juil. 2025, 22:46 UTC

Acquisitions, Fusions, Rachats

FTC Also Says Exxon Order Disregarded Guidelines and Precedent

17 juil. 2025, 22:43 UTC

Acquisitions, Fusions, Rachats

FTC: Maintaining Restrictions on John Hess's Employment Would 'Damage the FTC's Credibility'

17 juil. 2025, 22:43 UTC

Acquisitions, Fusions, Rachats

FTC: Chevron Order Disregarded FTC Merger Guidelines and Decades of Precedent

17 juil. 2025, 22:40 UTC

Acquisitions, Fusions, Rachats

FTC Reopens and Sets Aside Chevron-Hess and Exxon-Pioneer Final Consent Orders

17 juil. 2025, 22:40 UTC

Acquisitions, Fusions, Rachats

FTC Reopens and Sets Aside Chevron-Hess and Exxon-Pioneer Final Consent Orders

17 juil. 2025, 22:30 UTC

Market Talk
Résultats

Netflix Sticks to Its Playbook as Competitive Landscape Changes -- Market Talk

17 juil. 2025, 22:20 UTC

Market Talk
Résultats

Global Equities Roundup: Market Talk

17 juil. 2025, 22:20 UTC

Market Talk
Résultats

Netflix Focusing Resources on TV Viewers It Hasn't Yet Captured -- Market Talk

17 juil. 2025, 22:04 UTC

Market Talk
Résultats

Netflix Redesign Done to Match Current Capabilities -- Market Talk

17 juil. 2025, 22:03 UTC

Acquisitions, Fusions, Rachats

China Threatens to Block Panama Ports Deal Unless Its Shipping Giant Is Part of It -- 2nd Update

17 juil. 2025, 21:58 UTC

Market Talk
Résultats

Netflix Internal Data Doesn't Indicate Weaker Consumer Sentiment -- Market Talk

17 juil. 2025, 21:57 UTC

Résultats

Netflix Earnings Soar Past Expectations. How a Weak Dollar Helped Boost Results. -- Barrons.com

17 juil. 2025, 21:47 UTC

Résultats

Netflix Raises Revenue, Margin Forecasts After Strong Second Quarter -- Update

17 juil. 2025, 21:45 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

17 juil. 2025, 21:45 UTC

Market Talk

Crypto Bills Welcomed by Venture Capital, Trade Group Says -- Market Talk

17 juil. 2025, 21:38 UTC

Acquisitions, Fusions, Rachats

Railroad Operator Union Pacific Exploring Deal for Norfolk Southern -- 2nd Update

17 juil. 2025, 21:22 UTC

Acquisitions, Fusions, Rachats

Update: Union Pacific Considering a Norfolk Southern Buyout: Report. -- Barrons.com

17 juil. 2025, 21:05 UTC

Résultats

Netflix Earnings Soar Past Expectations. How a Weak Dollar Helped Boost Results. -- Barrons.com

17 juil. 2025, 21:04 UTC

Acquisitions, Fusions, Rachats

Railroad Operator Union Pacific Exploring Deal for Norfolk Southern -- Update

17 juil. 2025, 21:02 UTC

Acquisitions, Fusions, Rachats

Union Pacific Considering a Norfolk Southern Buyout: Report. -- Barrons.com

17 juil. 2025, 20:59 UTC

Acquisitions, Fusions, Rachats

Basel Medical Group Puts $1B Bitcoin Purchase on Hold

17 juil. 2025, 20:50 UTC

Market Talk
Résultats

Tech, Media & Telecom Roundup: Market Talk

17 juil. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

Comparaison

Variation de prix

Amicus Therapeutics Inc prévision

Objectif de Prix

By TipRanks

154.37% hausse

Prévisions sur 12 Mois

Moyen 16 USD  154.37%

Haut 22 USD

Bas 12 USD

Basé sur 8 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

8 ratings

7

Achat

1

Maintien

0

Vente

Score Technique

By Trading Central

5.925 / 7.38Support & Résistance

Court Terme

Very Strong Bearish Evidence

Moyen Terme

Bullish Evidence

Long Terme

Bearish Evidence

Sentiment

By Acuity

13 / 376Classement par Soins de santé

Sentiment de l'Actualité

Très Fortes Indications Haussières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Supérieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Amicus Therapeutics Inc

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.